In the 1980s, Bosco had been one of the top five pharma eutical and chemicals companies, but by the year 2000. it dropped to the second tier. Like a lot of companies Bosco believed that sustainability was achieved through internal innovation by increasing its R&D expenditures rather than growing through acquisitions. As a result, when the industry began to consolidate, Bosco passed up some opportunities to participate. In addition, its focus on pharmaceuticals and its neglect of other businesses resulted in its having an unbalanced portfolio. Finally had Bosco's now-withdrawn cholesterol-lowering drug fu filled its potential, it would have been a $4 billion to $5 billion asset. During the two years after its 2005 withdrawal, Bosco's market value plummeted